MK-8245SCD inhibitor,potent and liver-selective CAS# 1030612-90-8 |
- A939572
Catalog No.:BCC5305
CAS No.:1032229-33-6
- MK-8245 Trifluoroacetate
Catalog No.:BCC1769
CAS No.:1415559-41-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1030612-90-8 | SDF | Download SDF |
| PubChem ID | 24988881 | Appearance | Powder |
| Formula | C17H16BrFN6O4 | M.Wt | 467.25 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 19 mg/mL (40.66 mM; Need ultrasonic and warming) | ||
| Chemical Name | 2-[5-[3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,2-oxazol-5-yl]tetrazol-2-yl]acetic acid | ||
| SMILES | C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O | ||
| Standard InChIKey | UJEAABFSXKCSGI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H16BrFN6O4/c18-12-2-1-10(19)7-13(12)28-11-3-5-24(6-4-11)15-8-14(29-22-15)17-20-23-25(21-17)9-16(26)27/h1-2,7-8,11H,3-6,9H2,(H,26,27) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | MK-8245 is an liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 values of 1 nM, 3 nM and 3 nM for human, rat and mouse SCD1. | |||||
| Targets | SCD1 (human) | SCD1 (rat) | SCD1 (mouse) | |||
| IC50 | 1 nM | 3 nM | 3 nM | |||
MK-8245 Dilution Calculator
MK-8245 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1402 mL | 10.7009 mL | 21.4018 mL | 42.8036 mL | 53.5045 mL |
| 5 mM | 0.428 mL | 2.1402 mL | 4.2804 mL | 8.5607 mL | 10.7009 mL |
| 10 mM | 0.214 mL | 1.0701 mL | 2.1402 mL | 4.2804 mL | 5.3505 mL |
| 50 mM | 0.0428 mL | 0.214 mL | 0.428 mL | 0.8561 mL | 1.0701 mL |
| 100 mM | 0.0214 mL | 0.107 mL | 0.214 mL | 0.428 mL | 0.535 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
MK-8245 is a potent and liver-selective inhibitor of stearoyl-CoA desaturase (SCD) with IC50 value of 1nM [1].
SCD1 represents a therapeutic target for the treatment of type II diabetes, dyslipidemia, obesity, and metabolic diseases. As an inhibitor of SCD1, MK-8245 shows potency in both the rat enzyme and hepatocyte assay. There are no significant differences in potencies between the rat, mouse, and human SCD1. MK-8245 is developed as a liver-targeting SCD inhibitor. It demonstrates a liver-targeted tissue distribution profile resulting from a substrate recognition by organic anionic transporter proteins (OATPs) [1, 2].
MK-8245 is effective at lowering glucose level. It can improve glucose clearance dose-dependently with ED50 value of 7mg/kg. In the chronic eDIO mouse study, MK-8245 shows prevention of body weight gain with the maximally efficacious dose of 20 mg/kg bid based on body weight and liver triglyceride reduction [1].
References:
[1] Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, Du X, Gordon R, Guay J, Guiral S, Hafey MJ, Hamelin E, Huang Z, Kennedy B, Lachance N, Landry F, Li CS, Mancini J, Normandin D, Pocai A, Powell DA, Ramtohul YK, Skorey K, Sørensen D, Sturkenboom W, Styhler A, Waddleton DM, Wang H, Wong S, Xu L, Zhang L. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96.
[2] Lachance N, Guiral S, Huang Z, Leclerc JP, Li CS, Oballa RM, Ramtohul YK, Wang H, Wu J, Zhang L. Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series. Bioorg Med Chem Lett. 2012 Jan 1;22(1):623-7.
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- Ethyl 3-(pyridin-2-ylamino)propanoate
Catalog No.:BCC8973
CAS No.:103041-38-9
- CTCE 9908
Catalog No.:BCC6366
CAS No.:1030384-98-5
- MK-4305
Catalog No.:BCC1760
CAS No.:1030377-33-3
- Alterlactone
Catalog No.:BCN7261
CAS No.:1030376-89-6
- Dehydroheliobuphthalmin
Catalog No.:BCN5844
CAS No.:103001-05-4
- Acetaminophen
Catalog No.:BCC5269
CAS No.:103-90-2
- 4'-Methylacetanilide
Catalog No.:BCC8714
CAS No.:103-89-9
- Phenylacetic Acid
Catalog No.:BCC8349
CAS No.:103-82-2
- N-Methylbenzylamine
Catalog No.:BCN1790
CAS No.:103-67-3
- Scutebarbatine M
Catalog No.:BCN8327
CAS No.:960302-92-5
- Benzyl cinnamate
Catalog No.:BCN5042
CAS No.:103-41-3
- AS 2034178
Catalog No.:BCC7996
CAS No.:1030846-42-4
- Bakuchiol
Catalog No.:BCN5845
CAS No.:10309-37-2
- 2-Amino-6-chloropurine
Catalog No.:BCC8540
CAS No.:10310-21-1
- Kinetensin (human)
Catalog No.:BCC5845
CAS No.:103131-69-7
- ABT-046
Catalog No.:BCC1326
CAS No.:1031336-60-3
- 4-(4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile hydrobromide
Catalog No.:BCC8648
CAS No.:103146-26-5
- UNC 3230
Catalog No.:BCC5618
CAS No.:1031602-63-7
- 14-Norpseurotin A
Catalog No.:BCN7262
CAS No.:1031727-34-0
- Pranlukast
Catalog No.:BCC4827
CAS No.:103177-37-3
- Fmoc-Tyr(3,5-I2)-OH
Catalog No.:BCC3264
CAS No.:103213-31-6
- Fmoc-Cys(Trt)-OH
Catalog No.:BCC3479
CAS No.:103213-32-7
- A939572
Catalog No.:BCC5305
CAS No.:1032229-33-6
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.[Pubmed:21661758]
J Med Chem. 2011 Jul 28;54(14):5082-96.
The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.
